Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Maintains Buy on Nerdy, Raises Price Target to $5

Needham Maintains Buy on Nerdy, Raises Price Target to $5

Needham analyst Ryan MacDonald maintains Nerdy (NYSE:NRDY) with a Buy and raises the price target from $4 to $5.

byBenzinga Newsdesk

August 16, 2022

1 minute read

Needham analyst Ryan MacDonald maintains Nerdy (NYSE:NRDY) with a Buy and raises the price target from $4 to $5.

NGM Bio Presents Preliminary Data From NGM120 Combo Trial In Pancreatic Cancer

By Vandana Singh

September 14, 6:44 AM

NGM Biopharmaceuticals Inc (NASDAQ:NGM) announced updated preliminary findings from its Phase 1b dose escalation trial of NGM120 in metastatic pancreatic cancer.…

NGM

AstraZeneca’s Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder

By Vandana Singh

June 9, 8:44 AM

AstraZeneca Plc (NASDAQ: AZN)

AZN

Analyst Ratings

Expert Ratings for Bio-Techne

By Benzinga Insights

December 7, 9:00 AM

Bio-Techne (NASDAQ:TECH) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish…

TECH

Cathay General Q4 EPS $1.33 Misses $1.37 Estimate

By Benzinga Newsdesk

January 25, 5:37 PM

Cathay General (NASDAQ:CATY) reported quarterly earnings of $1.33 per share which missed the analyst consensus estimate of $1.37 by 2.92 percent. This is a 35.71 percent increase over earnings of $0.98 per share from the

CATY

Needham Maintains Buy on Nerdy, Raises Price Target to $5

Related Posts

NGM Bio Presents Preliminary Data From NGM120 Combo Trial In Pancreatic Cancer

AstraZeneca’s Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder

Expert Ratings for Bio-Techne

Cathay General Q4 EPS $1.33 Misses $1.37 Estimate